Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIN-2787 in BRAF- or NRAS-mutant advanced solid tumors
NL-OMON56188Phase 1Active, not recruiting
- Sponsor
- Kinnate Biopharma Inc.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of exarafenib and binimetinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), melanoma and 2 more (4 arms), sponsored by Kinnate Biopharma Inc. Primary endpoints: Incidence of dose-limiting toxicities, Treatment-emergent adverse events and 5 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
exarafenibbinimetinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)melanomacolorectal cancer (CRC)thyroid cancer
Beyond the preview
Go deeper on NL-OMON56188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56188.